Therapeutic potential of interleukin-15 in cancer (Review)
| Autor: | Marioara Chiritoiu-Butnaru, Ovidiu Gabriel Bratu, Mihaela Surcel, Adriana Narcisa Munteanu, Florentina Ionita-Radu, Monica Neagu, Gheorghita Isvoranu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
cancer immunotherapy natural killer cells Oncogene business.industry medicine.medical_treatment T cells Cancer interleukin-15 Review General Medicine Immunotherapy Cell cycle medicine.disease Immune system Immunology and Microbiology (miscellaneous) Cancer immunotherapy Immunity Interleukin 15 combination immunotherapy medicine Cancer research business |
| Zdroj: | Experimental and Therapeutic Medicine |
| ISSN: | 1792-0981 |
| Popis: | The immune system is dysfunctional in cancer, and therapeutic approaches designated to restore immunity and increase long-term overall survival are desirable. The role of immunotherapy is to trigger the immune system to recognize and destroy tumor cells. Interleukin-15 (IL-15) is a member of the common gamma-chain (γc) cytokines that promote the differentiation and expansion of T cells, B cells and natural killer (NK) cells, leading to enhanced antitumor responses. This suggests that IL-15 is a promising candidate for anticancer therapy. Renewed interest in cancer immunotherapy has led to an increased number of preclinical studies and clinical trials that have investigated the reliability and potency of IL-15-based agents, not only as single therapy, but also in combination with others. This review provides a description of these studies which show the advantages and disadvantages of IL-15 as an immunotherapeutic agent. We present here the role of IL-15 and pharmacologically improved IL-15 superagonists as a single treatment or in combination with other therapeutic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |